prikaz prve stranice dokumenta Radiofrequency ablation as locoregional therapy for unresectable hepatic malignancies: initial results in 24 patients with 5-years follow-up
  Download
PDF 68.59 KB
Scientific paper - Original scientific paper
Radiofrequency ablation as locoregional therapy for unresectable hepatic malignancies: initial results in 24 patients with 5-years follow-up
Collegium Antropologicum, 32 (2008), 3; 703-707. urn:nbn:hr:105:399786
Majerović, Mate; Augustin, Goran; Jelinčić, Željko; Buković, Damir; Kekez, Tihomir; Matošević, Petar; Smuđ, Dubravko; Kinda, Emil; Golem, Ante Zvonimir

Cite this document

Majerović, M., Augustin, G., Jelinčić, Ž., Buković, D., Kekez, T., Matošević, P. ... Golem, A. Z. (2008). Radiofrequency ablation as locoregional therapy for unresectable hepatic malignancies: initial results in 24 patients with 5-years follow-up. Collegium Antropologicum, 32. (3), 703-707. Retrieved from https://urn.nsk.hr/urn:nbn:hr:105:399786

Majerović, Mate, et al. "Radiofrequency ablation as locoregional therapy for unresectable hepatic malignancies: initial results in 24 patients with 5-years follow-up." Collegium Antropologicum, vol. 32, no. 3, 2008, pp. 703-707. https://urn.nsk.hr/urn:nbn:hr:105:399786

Majerović, Mate, Goran Augustin, Željko Jelinčić, Damir Buković, Tihomir Kekez, Petar Matošević, Dubravko Smuđ, Emil Kinda and Ante Zvonimir Golem. "Radiofrequency ablation as locoregional therapy for unresectable hepatic malignancies: initial results in 24 patients with 5-years follow-up." Collegium Antropologicum 32, no. 3 (2008): 703-707. https://urn.nsk.hr/urn:nbn:hr:105:399786

Majerović, M., et al. (2008) 'Radiofrequency ablation as locoregional therapy for unresectable hepatic malignancies: initial results in 24 patients with 5-years follow-up', Collegium Antropologicum, 32(3), pp. 703-707. Available at: https://urn.nsk.hr/urn:nbn:hr:105:399786 (Accessed 09 November 2024)

Majerović M, Augustin G, Jelinčić Ž, Buković D, Kekez T, Matošević P, and sur.. Radiofrequency ablation as locoregional therapy for unresectable hepatic malignancies: initial results in 24 patients with 5-years follow-up. Collegium Antropologicum [Internet]. 2008 September [cited 2024 November 09];32(3):703-707. Available at: https://urn.nsk.hr/urn:nbn:hr:105:399786

M. Majerović, et al., "Radiofrequency ablation as locoregional therapy for unresectable hepatic malignancies: initial results in 24 patients with 5-years follow-up", Collegium Antropologicum, vol. 32, no. 3, pp. 703-707, September 2008. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:399786. [Accessed: 09 November 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Radiofrequency ablation as locoregional therapy for unresectable hepatic malignancies: initial results in 24 patients with 5-years follow-up
AuthorMate Majerović
AuthorGoran Augustin
AuthorŽeljko Jelinčić
AuthorDamir Buković
AuthorTihomir Kekez
AuthorPetar Matošević
AuthorDubravko Smuđ
AuthorEmil Kinda
AuthorAnte Zvonimir Golem
Author's institutionUniversity of Zagreb
School of Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
Radiofrequency ablation (RFA) is one treatment modality for unresectable liver metastases. Patients with hepatic malignancies (n = 24) underwent elective RFA. All tumors were ablated with a curative intent, with a margin of 1 cm, in a single session of RFA. The median diameter of tumor was 3.1 cm (range 1.7-6.9 cm). Studied patients were not candidates for resection due to multifocal hepatic disease, extrahepatic disease, proximity to major vascular structures or presence of cirrhosis with functional hepatic reserve inadequate to tolerate major hepatic resection. Complete tumor necrosis was achieved in 87.5% and tumor recurred in 3 patients (12.5%) with lesions larger than 5 cm. Distant intrahepatic recurrence was diagnosed in another 4 (16.7%). Distant metastases were found in 7 (29.2%) patients. Four of these 7 patients had also distant intrahepatic recurrence of disease. Two and 5-years survival rates were 41.7% (10 patients) and 8.3% (2 patients) respectively. RFA is safe and effective option for patients with unresectable hepatic malignancies smaller than 5 cm without distant metastatic disease. RF ablation resulted in complete tumor necrosis in 87.5% with 2 and 5-years survival rates much higher than with chemotherapy alone or only supportive therapy, when survival is measured in weeks or months. If RFA is unavailable, percutaneous ethanol injection therapy can be done but with inferior survival rates.
Abstract (croatian)
Radiofrekvencijska ablacija (RFA) jedan je terapijski modalitet za liječenje neresektabilnih jetrenih metastaza. Bolesnici sa jetrenim metastazama (n=24) podvrgnuti su elektivnoj RFA. Ablacija svih jetrenih metastaza vršena je u svrhu izliječenja (kurativno) sa 1 cm zdravog ruba tijekom jedne (jedine) operacije. Srednji promjer tumora iznosio je 3,1 cm (rang 1,7–6,9 cm). Bolesnici podvrgnuti zahvatu nisu bili kandidati za resekcijski zahvat zbog: multifokalnih jetrenih metastaza, ekstrahepatalne proširenosti bolesti, blizine velikih krvnih žila ili prisutne ciroze sa nedovoljnom hepatalnom rezervom koja bi preostala nakon resekcije. Kompletna tumorska nekroza postignuta je u 87,5%, a rekurencija tumora pojavila se u 3 (12,5%) bolesnika i to kod metastatskih lezija većih od 5 cm. Udaljena intrahepatalna rekurencija dijagnosticirana je u 4 bolesnika (16,7%). Udaljene metastaze verificirane su u 7 (29,2%) bolesnika. Kod 4 od tih 7 bolesnika također je bila prisutna i udaljena intrahepatalna rekurencija bolesti. Dvogodišnje i 5-godišnje stope preživljenja iznosile su 41,7% (10 bolesnika) i 8,3% (2 bolesnika). Tijekom 24 mjeseca praćenja, preživljenje je iznosilo 41,7% (10 bolesnika). RFA je sigurna i efikasna metoda kod bolesnika sa neresektabilnim hepatalnim metastazama manjim od 5 cm bez udaljene metastatske bolesti. RFA je rezultirala sa kompletnom tumorskom nekrozom u 87,5% slučajeva sa 2- i 5-godišnjim stopama preživljenja znatno dužim u odnosu na primjenu isključivo kemoterapije ili suportivne terapije kada se preživljenje mjeri u tjednima ili mjesecima. Ako RFA nije dostupna također je moguće primijeniti perkutanu instlaciju etanola koja daje ipak lošije rezultate.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleCollegium Antropologicum
Numberingvol. 32, no. 3, pp. 703-707
p-ISSN0350-6134
URN:NBNurn:nbn:hr:105:399786
Publication2008-09
Document URLhttps://hrcak.srce.hr/27044
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-03-28 11:07:04